Biocryst Pharmaceuticals Inc (NASDAQ:BCRX) price on current trading day, fall -0.21% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $7.05.
A look at the stock’s price movement, the level at last check in today’s session was $7.06, moving within a range at $6.96 and $7.105. The beta value (5-Year monthly) was 1.887. Turning to its 52-week performance, $8.88 and $4.03 were the 52-week high and 52-week low respectively. Overall, BCRX moved -5.56% over the past month.
Biocryst Pharmaceuticals Inc’s market cap currently stands at around $1.46 billion, with investors looking forward to this quarter’s earnings report slated for in February.
Analysts have a consensus estimate of 131.1M for the company’s revenue for the quarter, with a low and high estimate of 130.8M and 131.77M respectively. The average forecast suggests up to a 40.36% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 450.36M, representing a 35.89% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that BCRX is a Hold. On the other hand, the stock is on average a Hold as suggested by medium term indicators while long term indicators are putting the stock in Hold category.
13 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 2 analyst(s) rate the stock as a Hold, 11 recommend BCRX as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
BCRX’s current price about -7.25% and -6.73% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 39.30, while 7-day volatility ratio is 7.71% and 5.33% in the 30-day chart. Further, Biocryst Pharmaceuticals Inc (BCRX) has a beta value of 1.75, and an average true range (ATR) of 0.39. Analysts have given the company’s stock an average 52-week price target of $9, forecast between a low of $7 and high of $11. Looking at the price targets, the low is 0.71% off recent price level in today’s trading while to achieve the yearly target high, it has to move -56.03%. Nonetheless, investors will most likely welcome a -27.66% jump to $9 which is the analysts’ median price.
If we refocus on Biocryst Pharmaceuticals Inc (NASDAQ:BCRX), historical trading data shows that trading volumes averaged 2.47 over the past 10 days and 2.13 million over the past 3 months. The company’s latest data on shares outstanding shows there are 207.12 million shares.
The 5.66% of Biocryst Pharmaceuticals Inc’s shares are in the hands of company insiders while institutional holders own 82.18% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 15.72 million on 2024-12-31, giving us a short ratio of 8.6. The data shows that as of 2024-12-31 short interest in Biocryst Pharmaceuticals Inc (BCRX) stood at 765.0 of shares outstanding, with shares short falling to 19.36 million registered in 2024-11-29. Current price change has pushed the stock -6.32% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the BCRX stock continues to rise going into the next quarter.
